Skip to main content

Table 7 Outcomes predicted by models for one birth cohort in Afr-region

From: Comparative review of three cost-effectiveness models for rotavirus vaccines in national immunization programs; a generic approach applied to various regions in the world

 

POLYMODa

Roxanne

CoRoVa

Undiscounted cases

   

   Mild

92,989

121,312

128,807

   Moderate

49,051

70,126

54,559

   Severe

5,092

9,589

5,277

   Nosocomial

1,680

1,986

2,701

   Deaths

955

1,789

1,524

   Outpatient

54,143

70,126

54,559

   Inpatient (comm. acq.)

5,092

9,589

5,277

Discounted savings

   

   Outpatient

$568,502

$716,305

$623,977

   Inpatient

$973,247

$1,329,538

$753,884

   Indirect

$108,916

$106,377

$81,486

   Discounted net costsb (*1000)

$6,759

$ 8,757-17,094

$ 9,250-17,467

Discounted QALYs

   

   Mortality

24,962

45,817

39,070

   Morbidity

542

762

628

  1. a. Approximation for one cohort from the multi-cohort results; b. Health-care perspective and range given for previous upper and lower vaccine prices if appropriate.